InstalabDrug Screen (12-Panel)
Should you take a Urine Drug Screen test?
This test is most useful if any of these apply to you.
12 biomarkers included
- Amphetamine ScreenScreens for amphetamine stimulants, including prescription attention-disorder drugs, a class prone to false positives from unrelated medications.A positive amphetamine result is among the least specific in the panel and often needs confirmation.
- Methadone ScreenIdentifies methadone, used for addiction treatment and chronic pain, and often combined with sedatives in ways that raise overdose risk.Methadone alongside benzodiazepines is a co-use pattern strongly linked to fatal slowing of breathing.
- Benzodiazepines ScreenDetects sedatives like alprazolam and diazepam that dangerously amplify opioid effects, though many newer versions evade the assay.A positive points to sedative use that compounds opioid risk; a negative does not rule out newer designer sedatives.
- Barbiturates ScreenChecks for older sedatives still used for seizures and some headaches, drugs that are dangerous in combination and overdose.A positive indicates barbiturate exposure, a sedative class with a narrow margin between effective and toxic doses.
- Tricyclic Antidepressants ScreenDetects older antidepressants that remain widely prescribed and are among the most dangerous medications in overdose.A positive flags tricyclic exposure but cannot distinguish a stable therapeutic dose from a toxic overdose.
- THC/Cannabinoids ScreenDetects the breakdown product of cannabis, which lingers far longer than other drugs, especially after regular use.A positive result can reflect cannabis use from days or even weeks earlier, not necessarily recent intoxication.
- Methamphetamine ScreenTargets methamphetamine specifically, a potent stimulant increasingly found laced with fentanyl in the illicit supply.A positive result signals methamphetamine use and a rising chance of unintended opioid co-exposure.
- Phencyclidine ScreenScreens for PCP (phencyclidine), a dissociative drug that is now uncommon but produces severe agitation and is prone to false positives.A positive result warrants confirmation, since several common medications can trigger a false phencyclidine signal.
- Cocaine/Metabolites ScreenMeasures benzoylecgonine, cocaine's main breakdown product, making it one of the most specific tests in the panel.A positive result reliably indicates recent cocaine use and increasingly carries a hidden fentanyl contamination risk.
- MDMA ScreenA dedicated test for MDMA (ecstasy), a stimulant club drug that standard amphetamine assays do not reliably capture.A positive result identifies MDMA use specifically, common in recreational and festival settings.
- Oxycodone ScreenA dedicated test for oxycodone, which general opiate assays often miss, capturing a widely prescribed and frequently misused opioid.A positive result signals oxycodone use specifically, since routine opiate screens frequently fail to detect it.
- Morphine/Opiates ScreenDetects morphine and related natural opiates such as codeine and heroin's breakdown products, the class most tied to overdose and prescription misuse.A positive result flags recent opiate exposure but cannot alone separate prescribed codeine from heroin without confirmatory testing.
About Drug Screen (12-Panel)
A single cup of urine can show, within minutes, whether twelve different drugs have passed through your body in recent days. That breadth is the point. Real substance use rarely stays inside one category, and a narrow test cannot see the combinations that carry the most danger.
This panel screens for the drugs and medications most tied to overdose, misuse, and risky mixing, all from one sample. It is a fast first look rather than a final verdict, but it answers a question no single test can: what is present, together, right now.
What This Panel Reveals
The largest group of tests covers opioids, the class involved in most overdose deaths. Three separate assays matter here because one general opiate test misses much. One catches morphine and heroin's chemical fingerprints, a second is dedicated to oxycodone, and a third finds methadone. Read together, they show whether someone is taking a prescribed opioid, an unauthorized one, or several at once. In chronic pain patients, illicit drug use occurred in 10.8% of positive specimens.
A second theme is sedatives, drugs that slow breathing. The benzodiazepine and barbiturate tests flag calming medications that turn dangerous when stacked on opioids. In addiction treatment data, methadone and benzodiazepines were co-detected in over two-thirds of samples, a combination tied to fatal slowing of breathing.
The stimulant tests cover cocaine, amphetamines, methamphetamine, and MDMA (the club drug ecstasy). These reveal a different risk, and increasingly a hidden one. Illicit stimulants are now often contaminated with fentanyl. Between 2013 and 2018, fentanyl found in cocaine-positive urine samples rose from 0.9% to 17.6%, so a positive stimulant result can carry an opioid danger the user never intended.
The remaining tests round out the picture. The cannabis test detects marijuana, which lingers longest of all. The phencyclidine test screens for PCP, a dissociative drug. The tricyclic antidepressant test flags an older, unusually lethal medication class. In one medical examiner analysis, methadone-positive deaths were more than twice as likely to be accidental overdoses when a tricyclic was also present, and more than four times as likely when both a tricyclic and a sedative appeared.
How to Read Your Results Together
The value of the panel is in the combinations. A single positive tells you little; a pattern tells you a great deal about risk and next steps.
| Pattern | What It Suggests |
|---|---|
| Methadone positive and benzodiazepines positive | The highest-risk sedative and opioid combination detected by this panel, raising overdose danger even at prescribed doses. |
| Cocaine or methamphetamine positive | Recent stimulant use with a growing chance of hidden fentanyl, worth a separate fentanyl test. |
| Prescribed opioid absent, a different opioid present | Possible non-adherence or unauthorized use, warranting an honest conversation and confirmation. |
| Amphetamine or phencyclidine positive with no known exposure | Often a false positive from an unrelated medication, so confirm before drawing conclusions. |
Timing shapes every result. Most drugs here clear within a few days, so a negative screen means nothing was above the cutoff during that window, not that nothing was ever used. Cannabis is the exception and can stay detectable for weeks after regular use. For stimulants like methamphetamine, the lab's cutoff can lengthen the detection window by more than a day.
When Results Can Be Misleading
Every test in this panel is a presumptive screen, meaning it uses antibodies that can react with look-alike molecules. False positives are well documented across the panel: between 3.9% and 9.9% of positive amphetamine screens turn out to be false, and everyday medications can trigger positives for phencyclidine, benzodiazepines, and tricyclics. A positive tricyclic result appeared in 27 of 28 people across blood levels ranging from harmless to very toxic, so it flags exposure, not severity.
The panel also has blind spots. It does not detect fentanyl, many newer designer sedatives, or most novel synthetic drugs, so a clean result is not proof of abstinence. Diluting or tampering with a sample can hide real use as well.
What to Do with Your Results
Treat any unexpected positive as a starting point, not a conclusion. A confirmatory laboratory method called mass spectrometry can identify the exact drug and rule out cross-reactivity, and it should be run before any consequential decision. Positive predictive value varied widely in one outpatient study, from 100% for cocaine and cannabinoids down to 9.3% for amphetamines, which is why confirmation matters most for the least specific tests.
If you are monitoring a prescription or your own recovery, repeat testing matters more than any single result. In addiction treatment, weekly testing was associated with modestly better retention in care. Retesting on a regular schedule, and after any change, turns a snapshot into a trend, and a licensed clinician or medical review officer can help interpret unexpected findings alongside your medication list.